Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799092 | 0.85 | NPC1 (0.61) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL11838896 | 0.84 | MAPT (0.84) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL6376293 | 0.82 | AR (0.62) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL22862421 | 0.81 | CYP1A2 (0.66) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL10832371 | 0.81 | NPC1 (0.57) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL9483568 | 0.81 | SMN1; SMN2 (0.59) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL6630458 | 0.81 | RAB9A (0.65) | MEN1KMT2AGAAMAPTBLM | |
| Hydrochloric Acid SCHEMBL28494253 | 0.81 | AR (0.60) | MEN1KMT2AGAAMAPTBLM | |
| SCHEMBL339813 | 0.80 | LMNA (0.82) | GAAMAPTCYP1A2CYP2C19LMNA | |
| SCHEMBL4667164 | 0.80 | MAPT (1.00) | MEN1KMT2AGAAMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-7786162-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | Raptor Pharmaceutical Corp. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | TORREYPINES THERAPEUTICS (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | MEN1 2576/4885KMT2A 4287/4885GAA 128/4885 |
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, NTPCR, GUSB | MEN1 3533/4885KMT2A 2949/4885GAA 749/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | MEN1 2929/4885KMT2A 625/4885GAA 1700/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | MEN1 3837/4885KMT2A 2973/4885GAA 318/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | MEN1 2894/4885KMT2A 2347/4885GAA 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.